Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference
Findings Provide Further Support for the Rationale Behind Bionor Pharma`s Second HIV Vaccine, Vacc-C5 (Oslo, 5 April 2013) Bionor Pharma ASA (OSE: BIONOR) today announced that their scientific work entitled “The C5 region of HIV-1 gp120 shares homology with the shared epitope of HLA-DRß1 and activates immune responses. Anti-C5 antibodies correlate with protection from HIV-1 disease …